Expression of proliferating cell nuclear antigen (PCNA) in multiple myeloma: Its relationship to bone marrow microvessel density and other factors of disease activity

International Journal of Immunopathology and Pharmacology

Volumn 17, Issue 1, 2004, Pages 49-56

  Alexandrakis, Michael G ^a   Passam, F H ^b   Pappa, C A ^a   Dambaki, C ^a   Sfakiotaki, G ^a   Alegakis, A K ^a   Kyriakou, D S ^c   Stathopoulos, E ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

^c UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

Angiogenesis; Cell proliferation; Interleukin 6; Microvessel density; Multiple myeloma; PCNA

Indexed keywords

CD34 ANTIBODY; CD34 ANTIGEN; CYCLINE; INTERLEUKIN 6; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGENESIS; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CAPILLARY DENSITY; CELL INFILTRATION; CELL KINETICS; CELL PROLIFERATION; CORRELATION ANALYSIS; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MICROVESSEL DENSITY; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; STAINING; ANALYSIS OF VARIANCE; BIOSYNTHESIS; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MICROCIRCULATION; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); NONPARAMETRIC TEST; PATHOPHYSIOLOGY; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BONE MARROW; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MALE; MICROCIRCULATION; MIDDLE AGED; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PROLIFERATING CELL NUCLEAR ANTIGEN; STATISTICS, NONPARAMETRIC;

EID: 5444275347     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200401700107     Document Type: Article

References (40)

1. Miguel Garcia A., E. Matutes, F. Tarin, J. Garcia-Talavera, A. Miguel -Sosa, F. Carbonell and D. Catovsky. 1995. Circulating Ki-67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy. J. Clin. Pathol. 48:835.
2. Skopelitou A., S. Tselenis, S. Theocharis, N. Agnantis, A. Tsenga, J. Elemenoglou, M. Hadjiyannakis and C. Kittas. 1994. Expression of proliferating cell nuclear antigen (PCNA) and nuclear organizer regions (NORS) in multiple myeloma. Anticancer Res. 14:787.
3. Shiratsuchi M., K. Muta, Y. Abe, S. Motomura, F. Taguchi, H. Takatsuki, N. Uike, T. Umemura, H. Nawata and J. Nishimura. 2002. Clinical significance of telomarase activity in multiple myeloma. Cancer 94:2232.
4. Mathews M.B., R.M. Bernstein, B.R. Franza and J.I. Garrels. 1984. Identity of the proliferating cell nuclear antigen and cyclin. Nature 309:374.
5. Hall P.A., D.A. Levison, A.L. Woods, C.C. Yu, D.B. Kellock, J.A. Watkins, D.M. Barnes, C.E. Gillett, R. Camplejohn, R. Dover, N.H. Waseem and D.P. Lane. 1990. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J. Pathol. 162:285.
6. Robbins B.A., D. de-La Vega, K. Ogata, E.M. Tan and R.M. Nakamura. 1987. Immunohistochemical detection of proliferating cell nuclear antigen in solid human malignancies. Arch. Pathol. Lab. Med. 111:841.
7. Celis J.E. and A. Celis. 1985. Cell cycle dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: Subdivision of the S phase. Proc. Natl. Acad. Sci. (USA). 82:3262.
8. Korkolopoulou P., E. Patsouris, G. Pangalis, A. Tsenga, J. Elemenoglou, E. Thomas-Tsangli, D. Spandidos and C. Kittas. 1993. A comparative assesment of proliferating cell nuclear antigen, C-myc P62 and nucleolar organizer region staining in non Hodgkin's lymphomas: a histochemical and immunohistochemical study of 200 cases. Hum. Pathol. 24:371.
9. Folkman J. 1996. New prospectives in clinical oncology from angiogenesis research. Eur. J. Cancer. 14:2534.
10. Fox SB. 1997. Tumour angiogenesis and prognosis. Histopathology 30:294.
11. Folkman J. 1995. Angiogenesis in cancer, vascular rheumatoid and other disease. Nature Med. 1:27.
12. Vacca A., D. Ribatti, M. Presta, M. Minischetti, M. Iurlaro, R. Ria, A. Albini, F. Bussolino and F. Dammacco. 1999. Bone marrow neovascularization, plasma cell angiogenic potential and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93:3064.
13. Rajkumar S.V., T. Leong, P.C. Roche, R. Fonseca, A. Dispenzieri, M.Q. Lacy, J.A. Lust, T.E. Witzig, R.A. Kyle, M.A. Gertz and P.R. Greipp. 2000. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin. Cancer. Res. 6:3111.
14. Pruneri G., M. Ponzoni, A. Ferreri, N. Decarli, M. Tresoldi, F. Raggi, C. Baldessari, M. Fraschi, L. Baldini, M. Goldaniga, A. Neri, N. Corboni, F. Bertolini and G. Viale. 2002. Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br. J. Haematol. 118:817.
15. Vacca A., D. Ribatti, L. Roncali, G. Ranieri, G. Serio, F. Silvestris and F. Dammacco. 1994. Bone marrow angiogenesis and progression in multiple myeloma. Br. J. Haematol. 87:503.
16. Alexandrakis M.G., F.H. Passam, A. Boula, A. Christophoridou, G. Aloizos, P. Roussou and D.S. Kyriakou. 2003. Relationship between circulating serum soluble inteleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Ann. Haematol. 82:19.
17. 2 microglobulin predict survival independent of thimidine kinase and C-reactive protein in multiple myeloma. Blood. 81:3382.
18. Budke H., A. Orazi, R.S. Neiman, G. Cattoretti, K. John and M. Barberis. 1994. Assessment of cell proliferation in paraffin sections of normal bone marrow by the monoclonal antibodies Ki-67 and PCNA. Mod. Pathol. 7:860.
19. Kawano M., T. Hirano, T. Matsuda, T. Taga, Y. Horii, K. Iwato, H. Asaoku, B. Tang, O. Tanabe, H. Tanaka, A. Kuramoto and T. Kishimoto. 1988. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma. Nature. 332:83.
20. Klein B., X.G. Zhang, M. Jourdan, J. Content, F. Houssiau, L. Aarden, M. Piechaczyk and R. Bataille. 1989. Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by interleukin-6. Blood 73:517.
21. Hallek M., P.L. Bergsagel and K.C. Anderson. 1998. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91:3.
22. Thaler J., F. Fechner, M. Herold and H. Huber. 1994. Interleukin-6 in multiple myeloma: correlation with disease activity and Ki-67 proliferation index. Leuk. Lymphoma. 12:265.
23. Alexandrakis M.G., F.H. Passam, E.S. Ganotakis, K. Sfiridaki, I. Xilouri, K. Perisinakis, D.S. Kyriakou. 2003. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR) serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma. Clin. Lab. Haem. 25:41.
24. Pelliniemi T.T., K. Irjala, K. Mattila, K. Pulkki, A. Rajamaki, A. Tienhaara, M. Laakso and R. Lahtinen. 1995. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood. 85:765.
25. Nachbaur D., M. Herold, A. Maneschg and H. Huber. 1991. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann. Hematol. 62:54.
26. Durie B.G.M. and S.E. Salmon. 1975. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer. 36:842.
27. Taylor C.R and Cote R.J. 1994. Immunomicroscopy; a diagnostic tool for the surgical pathologist. WB Saunders Company, Philadelphia.
28. Sukpanichnant S., J.B. Cousar, A. Leelasiri, S.E. Graber, J.P. Greer and R.D. Collins. 1994. Diagnostic criteria and histologic grade in multiple myeloma: histologic and immunohistochemical analysis of 176 cases with clinical correlation. Hum. Pathol. 25:308.
29. Rozman C., E. Montserrat, J.M. Rodriguez-Fernandez, R. Ayats, T. Vallespi, R. Parody, A. Rios, D. Prados, M. Morey and F. Gomis. 1984. Bone marrow histologic pattern-the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood. 64:642.
30. Thiele J., J. Lorenzen, T.K. Zirbes, H.M. Kvasnicka, C. Schilling, M. Schwonzen, V. Diehl and R. Fisher. 1996. Apoptosis in acute myeloblastic leukemia: follow up study on trephine biopsies of the bone marrow. Leukemia Lymphoma. 22:77.
31. Thor A.D., S. Liu, D.H. Moore and S.M. Edgerton. 1999. Comparison of mitotic index in vitro bromodeoxyuridine labeling and MIB-1 assays to quantitate proliferation in breast cancer. J. Clin. Oncol. 17:470.
32. Joshua D.E., R.D. Brown and J. Gibson. 1994. Prognostic factors in myeloma: what they tell us about the pathophysiology of the disease. Leuk. Lymphoma. 15:375.
33. Chaidos A.I., M.C. Bai, S.A. Kamina, P.E. Kanavaros, N.J. Agnantis and K.L. Bourantas. 2002. Incidence of apoptosis and cell proliferation in multiple myeloma correlation with bcl-2 protein expression and serum levels of interleukin-6 (IL-6) and IL-6 receptor. Eur. J. Haematol. 69:90.
34. San Miguel J., R. Garcia-Sanz, M. Gonzalez, M. Moro, J. Hernandez, F. Ortega, D. Borrego, M. Carnero, F. Casanova, R. Jimenez, J. Portero and A. Orfao. 1995. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood. 85:448.
35. Wilson C.S., L.J. Medeiros, R. Lai, A.W. Butch, A. Mc Courty, K. Kelly and R.K. Brynes. 2001. DNA Topoisomerase II a in multiple myeloma: a marker of cell proliferation and not drug resistastance. Mod. Pathol. 14:886.
36. Skopelitou A., P. Korkolopoulou, A. Papanikolaou and M. Hadjiyannakis. 1993. Proliferating cell nuclear antigen (PCNA) in medullary thyroid carcinoma. J. Cancer. Res. Clin. Oncol. 119:379.
37. Zhang X.G., B. Klein and R. Bataille. 1989. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood. 74:11.
38. Anderson K.C., R.M. Jones, C. Morimoto, P. Leavitt and B.A. Barut. 1989. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood. 73:1915.
39. + T-cell subsets in the peripheral blood of patients with active pulmonary tuberculosis. Int. J. Immunopathol. Pharmacol. 16:247.
40. Kaneider N.C., A. Kaser, H. Tilg, G. Ricevuti and C.J. Wiedermann. 2003. CD40 ligand-dependent maturation of human monocyte-derived dendritic cells by activated platelets. Int. J. Immunopathol. Pharmacol. 16:225.